ATE286126T1 - Glialmitogene faktoren, ihre herstellung und verwendung - Google Patents

Glialmitogene faktoren, ihre herstellung und verwendung

Info

Publication number
ATE286126T1
ATE286126T1 AT93918139T AT93918139T ATE286126T1 AT E286126 T1 ATE286126 T1 AT E286126T1 AT 93918139 T AT93918139 T AT 93918139T AT 93918139 T AT93918139 T AT 93918139T AT E286126 T1 ATE286126 T1 AT E286126T1
Authority
AT
Austria
Prior art keywords
glialmitogenic
factors
production
molecules
encode
Prior art date
Application number
AT93918139T
Other languages
English (en)
Inventor
Andrew Goodearl
Paul Stroobant
Luisa Minghetti
Michael Waterfield
Mark Marchioni
Maio Su Chen
Ian Hiles
Original Assignee
Ludwig Inst Cancer Res
Cambridge Neuroscience Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Cambridge Neuroscience Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE286126T1 publication Critical patent/ATE286126T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicinal Preparation (AREA)
AT93918139T 1992-06-30 1993-06-29 Glialmitogene faktoren, ihre herstellung und verwendung ATE286126T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90713892A 1992-06-30 1992-06-30
US94038992A 1992-09-03 1992-09-03
US96517392A 1992-10-23 1992-10-23
US08/036,555 US5530109A (en) 1991-04-10 1993-03-24 DNA encoding glial mitogenic factors
PCT/US1993/006228 WO1994000140A1 (en) 1992-06-30 1993-06-29 Glial mitogenic factors, their preparation and use

Publications (1)

Publication Number Publication Date
ATE286126T1 true ATE286126T1 (de) 2005-01-15

Family

ID=27488375

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93918139T ATE286126T1 (de) 1992-06-30 1993-06-29 Glialmitogene faktoren, ihre herstellung und verwendung

Country Status (11)

Country Link
US (8) US5530109A (de)
EP (1) EP0653940B1 (de)
JP (1) JP4127567B2 (de)
KR (2) KR100344006B1 (de)
AT (1) ATE286126T1 (de)
AU (2) AU688270B2 (de)
CA (1) CA2139136A1 (de)
DE (1) DE69333731T2 (de)
ES (1) ES2236686T3 (de)
PT (1) PT101297B (de)
WO (1) WO1994000140A1 (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7115554B1 (en) * 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US7319019B1 (en) * 1991-04-10 2008-01-15 Acorda Therapeutics, Inc. Glial mitogenic factors lacking an N-terminal signal sequence
US5716930A (en) * 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US20050106666A1 (en) * 1991-04-10 2005-05-19 Cambridge Neuroscience Glial mitogenic factors, their preparation and use
US6087323A (en) * 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
US7037888B1 (en) * 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
EP0656069A4 (de) * 1992-08-10 1996-07-10 Cambridge Neuroscience Inc Inhibitoren der zellproliferation, ihre herstellung und nutzung.
US5770567A (en) * 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
US6750196B1 (en) * 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
US5670342A (en) * 1995-04-06 1997-09-23 Amgen Inc. NDF peptides
US5721139A (en) * 1995-05-10 1998-02-24 Genentech, Inc. Isolating and culturing schwann cells
US5849585A (en) * 1995-05-10 1998-12-15 Genetech, Inc. Isolating and culturing Schwann cells
US6033660A (en) * 1995-05-10 2000-03-07 Genentech, Inc. Method of treating a nervous system injury with cultured schwann cells
GB9514325D0 (en) * 1995-07-13 1995-09-13 Royal Free Hosp School Med Detection and quantification of human herpes virus 7 by enzymic amplification
US5912326A (en) * 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
DE69732711T2 (de) 1996-07-12 2006-03-16 Genentech, Inc., South San Francisco Gamma-heregulin
CA2258721C (en) 1996-07-12 2014-09-09 Genentech, Inc. Chimeric heteromultimer adhesins
US5955111A (en) * 1996-10-08 1999-09-21 Hartford Hospital Methods and compositions for inducing production of stress proteins
US6387638B1 (en) 1997-02-10 2002-05-14 Genentech, Inc. Heregulin variants
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
AU745324B2 (en) * 1997-10-14 2002-03-21 Cenes Pharmaceuticals, Inc. Therapeutic methods comprising use of a neuregulin
WO1999031505A1 (en) * 1997-12-15 1999-06-24 Shire Laboratories Inc. Neurotrophic factor assay
US20010023241A1 (en) 1998-02-04 2001-09-20 Sliwkowski Mark X. Use of heregulin as a growth factor
US6110718A (en) * 1998-03-20 2000-08-29 Wayne State University Mammalian putative phosphatidylinositol-4-phosphate-5-kinase
US6051401A (en) * 1998-07-28 2000-04-18 Bayer Corporation Methods and constructs for protein expression
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US6933122B1 (en) * 1999-05-14 2005-08-23 The Trustees Of Columbia University In The City Of New York A-form of cytoplasmic domain of nARIA (CRD-neuregulin) and uses thereof
CA2399452A1 (en) 2000-02-11 2001-08-16 Proteosys Ag. Use of neuregulin-.beta. as an indicator and/or target
AU4951501A (en) * 2000-03-27 2001-10-08 Genetics Inst Methods for purifying highly anionic proteins
AU2001274947B2 (en) 2000-05-23 2006-08-17 Acorda Therapeutics, Inc. Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
EP2418218A1 (de) * 2001-08-06 2012-02-15 ProteoSys AG Neuregulin-Beta Isoformen assoziiert mit neuronalen Prozessen
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
EP1660628A4 (de) * 2003-08-19 2010-03-31 Agos Biotech Ltd Spleissvarianten von erbb-liganden, zusammensetzungen und verwendungen davon
TWI276685B (en) * 2003-12-30 2007-03-21 Ind Tech Res Inst Conditional medium for culturing Schwann cells
EP1781709A4 (de) * 2004-08-27 2011-07-06 Absorbent Technologies Inc Superabsorbierende polymere in landwirtschaftlichen anwendungen
KR100680479B1 (ko) * 2005-04-11 2007-02-08 주식회사 하이닉스반도체 비휘발성 메모리 장치의 프로그램 검증 방법
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
ES2530526T3 (es) 2005-12-30 2015-03-03 Zensun Shanghai Science And Technology Ltd Liberación extendida de neurregulina para mejorar la función cardíaca
US9580515B2 (en) * 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
US7521535B2 (en) * 2006-09-20 2009-04-21 The Board Of Regents For Oklahoma State University Anti-microbial defensin-related peptides and methods of use
BRPI0810631A2 (pt) 2007-05-10 2017-05-09 Acorda Therapeutics Inc métodos para detecção de dano cardíaco
US20090156488A1 (en) * 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
JP5650537B2 (ja) 2007-11-16 2015-01-07 マインド−エヌアールジー ソシエテ アノニムＭｉｎｄ−ＮＲＧ ＳＡ 活性のある溶解性の翻訳後修飾されたニューレグリン−アイソフォーム
WO2009108390A2 (en) 2008-02-29 2009-09-03 Acorda Therapeutics, Inc. Method for achieving desired glial growth factor 2 plasma levels
US9348975B2 (en) * 2008-05-02 2016-05-24 Baxter International Inc. Optimizing therapy outcomes for peritoneal dialysis
US8882700B2 (en) 2008-05-02 2014-11-11 Baxter International Inc. Smart patient transfer set for peritoneal dialysis
US8057679B2 (en) 2008-07-09 2011-11-15 Baxter International Inc. Dialysis system having trending and alert generation
US20110166068A1 (en) 2008-07-17 2011-07-07 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Pro-phylaxis of Heart Failure
EP3777878A1 (de) 2008-08-15 2021-02-17 Acorda Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung während nicht akuter zeiträume nach neurologischen verletzungen des zns
EP2370093A4 (de) * 2008-11-28 2012-08-29 Zensun Shanghai Science And Technology Ltd Neuregulin und kardiale stammzellen
EP2370458B1 (de) 2008-11-28 2014-10-15 Zensun (Shanghai) Science and Technology Limited Neuregulin-peptide und ihre verwendung
EP2391404B1 (de) 2009-01-30 2013-01-16 Baxter International Inc. Transfersets zur therapieoptimierung
US8282829B2 (en) 2009-05-20 2012-10-09 Baxter International Inc. System and method for automated data collection of twenty-four hour ultrafiltration and other patient parameters using wired or wireless technology
ES2748886T3 (es) 2009-06-09 2020-03-18 Zensun Shanghai Science & Tech Co Ltd Métodos basados en Neuregulina para el tratamiento de la insuficiencia cardíaca
ES2575125T3 (es) 2009-06-09 2016-06-24 Zensun (Shanghai) Science And Technology Limited Métodos basados en Neuregulina para el tratamiento de la insuficiencia cardíaca
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
NZ625673A (en) * 2009-10-14 2015-11-27 Acorda Therapeutics Inc Use of a neuregulin to treat peripheral nerve injury
US9020827B2 (en) 2009-10-16 2015-04-28 Baxter International Inc. Peritoneal dialysis optimized using a patient hand-held scanning device
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
EP3842059A1 (de) 2012-03-30 2021-06-30 Acorda Therapeutics, Inc. Ggf2 zur behandlung von chirurgikalen peripheren nervenläsionen oder neuropathischen schmerzen davon
AU2012392119B2 (en) 2012-10-08 2018-07-26 Zensun (Shanghai) Science & Technology, Co. Ltd. Compositions and methods for treating heart failure in diabetic patients
JP6542678B2 (ja) 2013-03-06 2019-07-10 アコーダ セラピューティクス インコーポレイテッド 心不全の治療または予防のためのニューレグリンまたはその断片の治療的投与の方法
EP3895724B1 (de) 2013-05-22 2025-06-25 Zensun (Shanghai) Science and Technology, Co., Ltd. Verlängerte freisetzung von neuregulin zur behandlung von herzinsuffizienz
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
WO2015140351A1 (en) 2014-03-21 2015-09-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing myelination
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
WO2017053794A1 (en) 2015-09-25 2017-03-30 Sawyer Douglas B Methods for treating cardiac injury
FI3774859T3 (fi) 2018-04-11 2024-05-24 Salubris Biotherapeutics Inc Ihmisen neureguliini-1:n (nrg-1) rekombinanttifuusioproteiinikoostumukset ja niiden käyttömenetelmät
CN111407881A (zh) 2019-01-07 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
JP2022547335A (ja) 2019-09-16 2022-11-11 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． 組換えヒトニューレグリン誘導体及びその使用
CN113289002A (zh) 2020-02-24 2021-08-24 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物
CA3222782A1 (en) 2021-06-10 2022-12-15 Amgen Inc. Engineered nrg-1 variants with improved selectivity toward erbb4 but not against erbb3
AU2023233680A1 (en) 2022-03-15 2024-10-17 Salubris Biotherapeutics, Inc. Methods of treating fibrosis and arrhythmia with a neuregulin-1 fusion protein
WO2025245112A1 (en) 2024-05-21 2025-11-27 Salubris Biotherapeutics, Inc. Neuregulin-1/anti-her3 antibody fusion protein for use in the treatment of heart failure

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935341A (en) * 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
US5214034A (en) * 1986-09-26 1993-05-25 Mitsui Toatsu Chemicals, Incorporated Catechol derivatives, and preventive and remedial preparations for regressive disorders in the central nervous system containing the same
US5019559A (en) * 1986-11-14 1991-05-28 President And Fellows Of Harvard College Wound healing using PDGF and IGF-II
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5057494A (en) * 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
DE69031120T2 (de) * 1989-05-19 1998-01-15 Genentech, Inc., South San Francisco, Calif. Her2 extrazellulare domäne
WO1991015230A1 (en) * 1990-04-06 1991-10-17 The Trustees Of The University Of Pennsylvania Ligand for the neu gene product
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
JPH05509079A (ja) * 1990-05-25 1993-12-16 ジョージタウン・ユニバーシティ ヒト癌遺伝子ｅｒｂＢ―２を過剰発現している細胞の増殖を阻害する増殖因子
US5202428A (en) * 1990-06-20 1993-04-13 The Salk Institute For Biological Studies DNA encoding neurotropic growth factor
DE69229597D1 (de) * 1991-01-14 1999-08-19 Univ Georgetown Wachstumsfaktor-ligand, der an den erbb-2-rezeptor bindet und die zellulären reaktionen induziert
GB9107566D0 (en) * 1991-04-10 1991-05-29 Ludwig Inst Cancer Res Glial mitogenic factors,their preparation and use
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
US5237056A (en) * 1991-05-29 1993-08-17 President And Fellows Of Harvard College DNA encoding a protein which copurifies with acetylcholine receptor inducing activity and uses therefor
WO1993022424A1 (en) * 1992-04-29 1993-11-11 Amgen Inc. RECOMBINANT STIMULATING FACTOR OF THE neu RECEPTOR
NZ252486A (en) * 1992-04-29 1997-08-22 Univ Georgetown Blocking peptides capable of binding to ligands of the epidermal growth factor receptor (erbb-2) and their use in detecting such ligands

Also Published As

Publication number Publication date
JP4127567B2 (ja) 2008-07-30
EP0653940B1 (de) 2004-12-29
US5792849A (en) 1998-08-11
US5854220A (en) 1998-12-29
US6147190A (en) 2000-11-14
KR100344006B1 (ko) 2002-12-11
US5621081A (en) 1997-04-15
AU4769493A (en) 1994-01-24
US5602096A (en) 1997-02-11
AU688270B2 (en) 1998-03-12
US5530109A (en) 1996-06-25
DE69333731D1 (de) 2005-02-03
US6232286B1 (en) 2001-05-15
DE69333731T2 (de) 2006-03-09
AU4833897A (en) 1998-04-23
EP0653940A1 (de) 1995-05-24
ES2236686T3 (es) 2005-07-16
JPH08509357A (ja) 1996-10-08
WO1994000140A1 (en) 1994-01-06
PT101297A (pt) 1994-06-30
EP0653940A4 (de) 1997-02-26
PT101297B (pt) 1999-10-29
KR100307943B1 (ko) 2001-12-01
CA2139136A1 (en) 1994-01-06
US5606032A (en) 1997-02-25

Similar Documents

Publication Publication Date Title
ATE286126T1 (de) Glialmitogene faktoren, ihre herstellung und verwendung
DE69839768D1 (de) Rekombinante lactoferrin, verfahren zu ihrer herstellung mittels pflanzen und ihre verwendung
DE69737507D1 (de) Neue nukleinsäuremoleküle aus mais und deren verwendung zur herstellung modifizierter stärke
DE3864585D1 (de) Dns-molekule, codierend fuer non-a-non-b-hepatitis-antigene und ihre verwendung zur herstellung dieser antigene.
DE69738586D1 (de) Hohe expressionsrate von proteinen
ATE310015T1 (de) Hohe expressionsrate des grün-fluoreszierenden proteins
DE69435038D1 (de) Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie
ATE155485T1 (de) Bpc-peptide, ihre herstellung und verwendung
DE69726884D1 (de) Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
ATE181056T1 (de) Arylessigsäurederivate und ihre verwendung als fungizide
DE69504808D1 (de) Corticotropin freisetzende rezeptoren des faktor 2
DE3853446D1 (de) Fibronectinbindungsprotein und dessen Herstellung.
EP0192175A3 (de) Polypeptide des Rhinovirusstammes HRV2 sowie die hierfür codierenden DNA-Moleküle
DE19781038T1 (de) Keratinozytenwachstumsfaktor-2-Produkte
DE69940022D1 (de) Promotoren für wachstums-differenzierungsfaktoren und deren verwendung
EP0261403A3 (de) Polypeptide des Rhinovirusstammes HRV89 sowie die hierfür codierenden DNA-Moleküle
ATE175237T1 (de) Polypeptide beteiligt an der kobalamin- und/oder kobamid-biosynthese, für diese kodierende dns- sequencen, und ihre herstellung und vewendung.
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
ATE61409T1 (de) Biosynthetische 2,5-diketogluconsaeurereduktase, verfahren, rekombinante zellen und expressionsvektoren fuer ihre herstellung und ihre verwendung zur bereitung von 2-keto-l-gulonsaeure.
ATE286968T1 (de) Isolierung und verwendung von nukleinsäuremolekülen, welche für mitglieder der ssx-familie kodieren
DE3783145D1 (de) Rekombinantes dns-plasmid zur herstellung von xanthangummi.
DE60225530D1 (de) Phosphorylierte glyoxalase i und deren verwendung
ATE99687T1 (de) Strobilurinderivate, ihre herstellung und verwendung.
DE59106119D1 (de) Stabilisatorkombinationen und ihre Verwendung zur Herstellung von stabilisierten, schlagzähmodifizierten Polyamiden.
IT8521507A0 (it) Vettore di clonaggio, molecole di dna ricombinante, ceppi di bacillus subtilis trasformati con dette molecole e metodi per l'espressione di geni eterologhi e produzione e secrezione di proteine codificate da detti geni.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties